Not independent
Tenure on this board
1.8 yrs
8 nominees · 2 ballot items.
Shareholders will vote to (1) approve the exercisability of 399,020 New Series C/D warrants at $5.00 and 13,966 Placement Agent Warrants at $6.25 issued in the May 18, 2026 Warrant Inducement Transaction (required under Nasdaq Rule 5635(d)), and (2) approve an increase to the authorized share capital by 10,000,000 ordinary shares (from 5,900,000 to 15,900,000) to provide capacity for future issuances and help maintain Nasdaq listing compliance.
Approval to permit the exercisability of (i) 399,020 aggregate new Series C and Series D warrants to purchase 399,020 ordinary shares at an exercise price of $5.00 per share (the New Warrants) issued as inducements to investors, and (ii) 13,966 placement agent warrants to purchase 13,966 ordinary shares at an exercise price of $6.25 per share (the Placement Agent Warrants), issued in the induced warrant exercise transaction completed on May 18, 2026, as required by Nasdaq Listing Rule 5635(d).
This management proposal asks shareholders to authorize the exercisability of 399,020 new Series C and D warrants (exercisable at $5.00) issued to investors and 13,966 placement agent warrants (exercisable at $6.25) issued to H.C. Wainwright as part of the May 18, 2026 Warrant Inducement Transaction. Management moved to condition exercisability on shareholder approval to comply with Nasdaq Listing Rule 5635(d) and to permit the immediate closing of the underlying induced exercise that restored the company’s shareholders’ equity above Nasdaq’s $2.5 million minimum. The board argues that approval is required by regulatory rules and by contractual commitments made to investors and the placement agent, and that enabling exercisability preserves the agreed terms of the financing while also creating the potential for additional cash proceeds if the warrants are exercised in the future. Exercise of all New Warrants and Placement Agent Warrants would generate approximately $1.995 million and $87.3 thousand of gross proceeds respectively, which management says would support funding for the company’s upcoming Phase 2/3 clinical trials for SIL-204 and bolster shareholders’ equity. The proposal is presented in the context of a recent 1-for-10 reverse share split and several concurrent financing-related transactions (ATM sales and note conversions) that consumed available authorized shares, creating timing and regulatory constraints. The board recommends “FOR” because without approval the company could not satisfy contractual commitments and might face Nasdaq compliance risks or constrained financing flexibility; however, approval would also create potential dilution and market overhang, which the board acknowledges in its risk disclosure. The board emphasizes that facilitating exercisability is both a remedial and prospective step: remedial to finalize the inducement transaction properly under Nasdaq rules, and prospective because it preserves a source of potential future financing. Investors evaluating the proposal should weigh the immediate corporate need to maintain Nasdaq listing and fund clinical development against the dilution risks and possible downward pressure on the share price that could result if warrants are exercised.
Approval to increase the company’s authorized share capital by 10,000,000 ordinary shares from US$796,500 divided into 5,900,000 shares to US$2,146,500 divided into 15,900,000 shares (par value US$0.135 each) to provide capacity for future issuances to support financing, equity incentives, and compliance with Nasdaq shareholders’ equity requirements.
This management proposal requests shareholder approval to amend the memorandum of association to increase authorized share capital by 10,000,000 ordinary shares (to a total of 15,900,000) to provide the company with the headroom needed for near- to mid-term financing and operational needs. Management cites depleted remaining unissued authorized shares—after recent ATM sales, induced warrant exercises, and conversion of the Moringa Sponsor note—as a constraint on the company’s ability to issue equity to raise capital or grant equity incentives. The stated purposes include enabling ongoing ATM sales, potential follow-on offerings, warrant exercises and conversion of notes, equity awards under the 2024 Plan, and potential acquisitions or business-development transactions. Management frames the increase as necessary both to maintain compliance with the Nasdaq $2.5 million shareholders’ equity requirement and to preserve the company’s Nasdaq listing, which it argues is critical to liquidity and future fundraising. The board asserts the proposed 10,000,000-share increase is the minimum required to meet projected needs in the short-to-mid term, and it commits to managing the enlarged authorized share capital to minimize unnecessary dilution. Approving the increase does not itself issue shares, but authorizes the company to issue a potentially substantial number of shares in future transactions—raising significant dilution and downward price pressure risks which management discloses in the proxy. If shareholders do not approve the increase, the company warns it may lack the capacity to achieve Nasdaq compliance and could face delisting or be forced into less favorable financing terms. Stakeholders should therefore weigh the tradeoff between immediate dilution risk and the strategic necessity of preserving listing status and securing financing for clinical development.
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | CITADEL ADVISORS LLC | 5.0% | 20,926 | $27K |
| 2 | TWO SIGMA SECURITIES, LLC | 2.8% | 11,657 | $15K |
| 3 | MONTAG A ASSOCIATES INC | 0.7% | 3,000 | $4K |
| 4 | UBS Group AG | 0.1% | 517 | $662 |
| 5 | Pflug Koory, LLC | 0.1% | 333 | $426 |
| 6 | JONES FINANCIAL COMPANIES LLLP | 0.0% | 26 | $32 |
| 7 | SBI Securities Co., Ltd. | 0.0% | 20 | $26 |
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.